Eisai, Biogen Say FDA Extends Review Of LEQEMBI IQLIK As A Starting Dose For Early AD

AI Briefing

• – Eisai and Biogen say FDA extends review of LEQEMBI IQLIK as a starting dose for early AD
• – US FDA extends review of LEQEMBI IQLIK for Alzheimer's disease
• – Eisai and Biogen await FDA decision on LEQEMBI IQLIK for early Alzheimer's